Not checkedNot checked for notices yet.
News in brief
Jack Williamson
The Lancet. Healthy Longevity · 2021
doi:10.1016/s2666-7568(21)00011-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The clinical value of convalescent plasma for treating patients with COVID-19 has been a key question of concern. Previously tested on patients who were moderately or severely ill with the disease, convalescent plasma provided only weak evidence of clinical efficacy. Another strategy, suggested by the Emergency Use Authorization, is to use high-titer convalescent plasma in patients shortly after onset of symptoms. In a multicentre, randomised controlled trial, Romina Libster (Fundación Infant, Buenos Aires, Argentina) and colleagues investigated 250 ml of convalescent plasma (with IgG titer >1:1000 against severe acute respiratory syndrome coronavirus 2 spike protein) versus placebo in 160 patients (mean age 77 years, including patients with coexisting conditions) within 72 h after the onset of mild COVID-19 symptoms.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.